Breaking News Instant updates and real-time market news.

2020-11-03 08:11:09 EDSA Edesa Biotech $6.05 / + (+0.00%) 08:11 11/03/20 11/03 08:11 11/03/20 08:11	Edesa Biotech completes enrollment of over 50% of patients for EB01 cream cohort Edesa Biotech announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candidate as a monotherapy for chronic allergic contact dermatitis. The adaptive, double-blind study is evaluating the safety and efficacy of EB01 cream in approximately 46 subjects in the first cohort. EB01 is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. In two previous clinical studies EB01 has demonstrated statistically significant improvement of multiple symptoms in ACD patients.
EDSA Edesa Biotech $6.05 / + (+0.00%) 03/30/20 Brookline Edesa Biotech initiated with a Buy at Brookline

2020-11-03 08:11:09

EDSA

Edesa Biotech

$6.05 / + (+0.00%)

08:11

11/03/20

11/03

08:11

11/03/20

08:11

Edesa Biotech completes enrollment of over 50% of patients for EB01 cream cohort

Edesa Biotech announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candidate as a monotherapy for chronic allergic contact dermatitis. The adaptive, double-blind study is evaluating the safety and efficacy of EB01 cream in approximately 46 subjects in the first cohort. EB01 is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. In two previous clinical studies EB01 has demonstrated statistically significant improvement of multiple symptoms in ACD patients.

EDSA Edesa Biotech

$6.05 / + (+0.00%)

03/30/20 Brookline: Edesa Biotech initiated with a Buy at Brookline

TODAY'S FREE FLY STORIES

Hot Stocks	Roche announces FDA acceptance of Genentech Esbriet sNDA » 05:35 01/21/21 01/21 05:35 01/21/21 05:35 RHHBY Roche $0.00 / + (+0.00%) Genentech, a member of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 01/12/21 Roche confirms U.S to buy additional doses of Regeneron's Cov-19 cocktail 01/07/21 Roche granted FDA orphan drug status for Atezolizumab in esophageal cancer 01/06/21 Pluristem appoints Maital Shemesh-Rasmussen, Rami Levi to board 01/05/21 Genentech announces tiragolumab granted Breakthrough Therapy Designation by FDA RHHBY Roche $0.00 / + (+0.00%) 01/15/21 Deutsche Bank Roche initiated with a Hold at Deutsche Bank 01/12/21 UBS Roche price target lowered to CHF 355 from CHF 365 at UBS 01/11/21 Berenberg Roche price target lowered to CHF 325 from CHF 350 at Berenberg 01/11/21 Benchmark Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RHHBY Roche $0.00 / + (+0.00%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/02/21 2021 London Global Healthcare Virtual Conference 02/04/21 Roche - RHHBY
Hot Stocks	Addex Therapeutics receives IND approval to start study in epilepsy » 05:33 01/21/21 01/21 05:33 01/21/21 05:33 ADXN Addex Therapeutics $10.49 / +0.04 (+0.38%) , JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) Addex Therapeutics (ADXN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/19/21 Royalty Pharma acquires royalty interest in Seltorexant from Minerva 01/19/21 Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M 01/15/21 Halozyme says Janssen receives FDA approval of Darzalex Faspro 01/15/21 Genmab says Janssen granted FDA approval for Darzalez Faspro ADXN JNJ ADXN Addex Therapeutics $10.49 / +0.04 (+0.38%) JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/15/21 B. Riley Securities Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 12/29/20 Piper Sandler Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/13/21 Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says 01/13/21 J&J chief science officer sees possible vaccine approval by March, Reuters says 01/13/21 J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says 01/13/21 EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 01/14/21 Fly Intel: Wall Street's top stories for Thursday 01/14/21 Fly Intel: Wall Street's top stories at midday 01/13/21 Fly Intel: Wall Street's top stories for Wednesday 12/29/20 Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades 01/26/21 Johnson & Johnson - JNJ JNJ JNJ Johnson & Johnson $162.30 / -0.45 (-0.28%) 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th
Hot Stocks	Galapagos announces NICE recommendation for Jyseleca on NHS » 05:27 01/21/21 01/21 05:27 01/21/21 05:27 GLPG Galapagos $108.63 / +0.89 (+0.83%) Galapagos announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events GLPG Galapagos $108.63 / +0.89 (+0.83%) 12/15/20 Galapagos to assume development, manufacturing, other rights for Jyseleca 12/15/20 Gilead will not pursue FDA approval of Jyseleca for RA 12/01/20 Galapagos announces 1st dosing in Mangrove trial in GLPG2737 with ADPKD patient 11/30/20 Galapagos presents results with GLPG1205 in IPF patients in Pinta trial GLPG Galapagos $108.63 / +0.89 (+0.83%) 01/19/21 Barclays Galapagos price target raised to $125 from $85.50 at Barclays 01/19/21 Morgan Stanley Galapagos upgraded to Overweight from Equal Weight at Morgan Stanley 12/18/20 Truist Gilead price target lowered to $62 from $67 at Truist 12/17/20 Maxim Galapagos price target lowered to $140 from $170 at Maxim GLPG Galapagos $108.63 / +0.89 (+0.83%) 08/06/20 Galapagos reports first half EPS EUR (2.55) vs. (1.76) last year GLPG Galapagos $108.63 / +0.89 (+0.83%) 12/16/20 Fly Intel: Wall Street's top stories for Wednesday 12/16/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Fly Intel: After-Hours Movers 08/19/20 Fly Intel: Wall Street's top stories for Wednesday 03/02/21 2021 London Global Healthcare Virtual Conference
Recommendations	Pinnacle Financial price target raised to $80 from $60 at Keefe Bruyette » 05:27 01/21/21 01/21 05:27 01/21/21 05:27 PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) Keefe Bruyette analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 10/20/20 Pinnacle Financial declares16c per share quarterly cash dividend PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 01/04/21 Wells Fargo Pinnacle Financial downgraded to Equal Weight from Overweight at Wells Fargo 12/15/20 JPMorgan Pinnacle Financial upgraded to Overweight from Neutral at JPMorgan 11/16/20 Stephens Pinnacle Financial resumed with an Overweight at Stephens 09/29/20 Truist Truist raises price targets on select regional banks PNFP Pinnacle Financial $72.53 / +2.21 (+3.14%) 01/19/21 Pinnacle Financial reports Q4 EPS $1.58 ex-items, consensus $1.35 01/19/21 Pinnacle Financial reports Q4 EPS $1.58 ex-items, consensus $1.35 01/19/21 Notable companies reporting after market close 10/20/20 Pinnacle Financial reports Q3 EPS $1.42, consensus $1.09 03/11/21 Virtual Atlanta and Texas Bank Summit
Upgrade	Barings BDC upgraded to Buy from Hold at Jefferies » 05:25 01/21/21 01/21 05:25 01/21/21 05:25 BBDC Barings BDC $9.08 / -0.025 (-0.27%) Jefferies analyst Kyle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BBDC Barings BDC $9.08 / -0.025 (-0.27%) 11/09/20 Barings BDC raises dividend to 17c from 16c 08/10/20 MVC Capital to merge into Barings BDC BBDC Barings BDC $9.08 / -0.025 (-0.27%) 08/18/20 Fly Intel: Top five analyst upgrades 08/17/20 Keefe Bruyette Barings BDC upgraded to Outperform from Market Perform at Keefe Bruyette 06/24/20 Raymond James Barings BDC upgraded to Strong Buy from Outperform at Raymond James 06/24/20 Raymond James Barings BDC upgraded to Strong Buy from Outperform at Raymond James BBDC Barings BDC $9.08 / -0.025 (-0.27%) 11/09/20 Barings BDC reports Q3 EPS 17c, consensus 15c 08/05/20 Barings BDC reports Q2 NII 14c, consensus 15c

Upgrade	Freshpet upgraded to Outperform from Perform at Oppenheimer » 05:25 01/21/21 01/21 05:25 01/21/21 05:25 FRPT Freshpet $146.47 / +2.39 (+1.66%) Oppenheimer analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly FRPT Freshpet $146.47 / +2.39 (+1.66%) 09/24/20 Freshpet completes CFO transition with appointment of Heather Pomerantz 08/31/20 Freshpet CFO Kassar sells 10,000 common shares 08/14/20 Freshpet launches multi-year corporate governance plan 08/03/20 Freshpet appoints Thembi Machaba as SVP, human resources FRPT Freshpet $146.47 / +2.39 (+1.66%) 01/19/21 Stephens Freshpet initiated with an Overweight at Stephens 01/19/21 JPMorgan Freshpet price target raised to $170 from $160 at JPMorgan 01/14/21 Truist Freshpet price target raised to $140 from $120 at Truist 01/11/21 Stifel Freshpet price target raised to $160 from $120 at Stifel FRPT Freshpet $146.47 / +2.39 (+1.66%) 01/13/21 Freshpet sees Q4 revenue $84.5M, consensus $88.41M 01/13/21 Freshpet sees Q4 net sales $84.5M, consensus $88.41M 01/13/21 Freshpet sees FY20 net sales $318.8M, consensus $322.73M 11/02/20 Freshpet backs FY20 revenue view $320M, consensus $321.89M 27 Feb FRPT Freshpet $146.47 / +2.39 (+1.66%) 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers
Downgrade	Equinor downgraded to Hold from Buy at Santander » 05:24 01/21/21 01/21 05:24 01/21/21 05:24 EQNR Equinor $19.67 / -0.14 (-0.71%) Santander analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events EQNR Equinor $19.67 / -0.14 (-0.71%) 12/15/20 KNOT Offshore Partners announces acquisition of Tove Knutsen shuttle tanker 11/18/20 Norsk Hydro, Panasonic and Equinor sign MOU to explore European battery business 10/19/20 TechnipFMC awarded EPC contract by Equinor for Breidablikk Pipelay 10/14/20 Equinor, Microsoft sign MoU to collaborate on Northern Lights project EQNR Equinor $19.67 / -0.14 (-0.71%) 01/15/21 JPMorgan Equinor price target raised to NOK 190 from NOK 180 at JPMorgan 01/14/21 Societe Generale Societe Generale downgrades three EU oil & gas names after strong performances 01/14/21 Societe Generale Equinor downgraded to Hold from Buy at Societe Generale 01/13/21 Credit Suisse Equinor price target raised to NOK 220 from NOK 205 at Credit Suisse 03/01/21 26th Annual Energy Virtual Summit
Hot Stocks	Calliditas Therapeutics announces full enrollment of NefIgArd trial » 05:23 01/21/21 01/21 05:23 01/21/21 05:23 CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) Calliditas Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) 01/20/21 Calliditas Therapeutics to provide data from Part A of NefIgArd study 01/18/21 Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile 11/09/20 Calliditas Therapeutics says Part A of NefIgArd trial met its primary objective CALT Calliditas Therapeutics $32.59 / +0.69 (+2.16%) 07/01/20 Citi Calliditas Therapeutics initiated with a Buy at Citi 06/30/20 Jefferies Calliditas Therapeutics initiated with a Buy at Jefferies 06/30/20 Stifel Calliditas Therapeutics initiated with a Buy at Stifel 05 Jun
Upgrade	Voestalpine upgraded to Accumulate from Hold at Erste Group » 05:23 01/21/21 01/21 05:23 01/21/21 05:23 VLPNY Voestalpine $0.00 / + (+0.00%) Erste Group analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research VLPNY Voestalpine $0.00 / + (+0.00%) 01/19/21 Morgan Stanley Voestalpine price target raised to EUR 26 from EUR 25.40 at Morgan Stanley 01/18/21 Credit Suisse Voestalpine upgraded to Neutral from Underperform at Credit Suisse 11/25/20 Deutsche Bank Voestalpine downgraded to Hold from Buy at Deutsche Bank 11/17/20 Morgan Stanley Voestalpine price target raised to EUR 18.50 from EUR 18 at Morgan Stanley
Upgrade	Palfinger upgraded to Accumulate from Hold at Erste Group » 05:22 01/21/21 01/21 05:22 01/21/21 05:22 PLFRY Palfinger $0.00 / + (+0.00%) Erste Group analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research PLFRY Palfinger $0.00 / + (+0.00%) 05/06/20 Berenberg Palfinger price target lowered to EUR 22 from EUR 23 at Berenberg 05/06/20 Kepler Cheuvreux Palfinger upgraded to Hold from Reduce at Kepler Cheuvreux

Upgrade	Grupo Mexico upgraded to Outperform from Underperform at Itau BBA » 05:22 01/21/21 01/21 05:22 01/21/21 05:22 GMBXF Grupo Mexico $0.00 / + (+0.00%) Itau BBA analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research GMBXF Grupo Mexico $0.00 / + (+0.00%) 01/06/21 Barclays Grupo Mexico initiated with an Equal Weight at Barclays 06/16/20 Goldman Sachs Southern Copper downgraded to Neutral from Buy at Goldman Sachs 06/08/20 Citi Grupo Mexico downgraded to Neutral from Buy at Citi 03/25/20 Morgan Stanley Grupo Mexico upgraded to Overweight from Equal Weight at Morgan Stanley
Earnings	TAL Education sees Q4 revenue $1.18B-$1.2B, consensus $1.17B » 05:21 01/21/21 01/21 05:21 01/21/21 05:21 TAL TAL Education $67.73 / -0.6 (-0.88%) Based on our current… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options TAL TAL Education $67.73 / -0.6 (-0.88%) 12/28/20 TAL Education announces $3.3B private placement with Silver Lake-led investors TAL TAL Education $67.73 / -0.6 (-0.88%) 12/30/20 Credit Suisse Credit Suisse cuts TAL target to $79 on margin pressure from online competition 12/29/20 CLSA TAL Education now has 'war chest' to fight competition, says CLSA 11/25/20 Morgan Stanley OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley 10/26/20 JPMorgan TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday) TAL TAL Education $67.73 / -0.6 (-0.88%) 05:19 Today TAL Education reports Q3 EPS 2c, consensus 7c 10/22/20 TAL Education sees Q3 revenue $1.06B-$1.09B, consensus $1.14B 10/22/20 TAL Education reports Q2 EPS 8c, consensus 12c 07/30/20 TAL Education sees Q2 revenue $1.08B-$1.11B, consensus $1.24B TAL TAL Education $67.73 / -0.6 (-0.88%) 08/07/20 Citon says authorities given info to end GSX Techedu 'charade' 08:00 Today TAL Education - TAL TAL TAL Education $67.73 / -0.6 (-0.88%) 09/03/20 Tal Education Group put volume heavy and directionally bearish
Initiation	Cyrela Brazil Realty initiated with a Buy at BTG Pactual » 05:21 01/21/21 01/21 05:21 01/21/21 05:21 CYRBY Cyrela Brazil Realty $0.00 / + (+0.00%) BTG Pactual initiated… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research CYRBY Cyrela Brazil Realty $0.00 / + (+0.00%) 08/28/20 JPMorgan Cyrela Brazil Realty upgraded to Overweight from Neutral at JPMorgan
Downgrade	Incitec Pivot downgraded to Neutral from Outperform at Credit Suisse » 05:20 01/21/21 01/21 05:20 01/21/21 05:20 INCZY Incitec Pivot $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research INCZY Incitec Pivot $0.00 / + (+0.00%) 08/06/20 Goldman Sachs Incitec Pivot upgraded to Buy from Neutral at Goldman Sachs 04/22/20 JPMorgan Incitec Pivot upgraded to Overweight from Neutral at JPMorgan
Earnings	TAL Education reports Q3 EPS 2c, consensus 7c » 05:19 01/21/21 01/21 05:19 01/21/21 05:19 TAL TAL Education $67.73 / -0.6 (-0.88%) Reports Q3 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options TAL TAL Education $67.73 / -0.6 (-0.88%) 12/28/20 TAL Education announces $3.3B private placement with Silver Lake-led investors TAL TAL Education $67.73 / -0.6 (-0.88%) 12/30/20 Credit Suisse Credit Suisse cuts TAL target to $79 on margin pressure from online competition 12/29/20 CLSA TAL Education now has 'war chest' to fight competition, says CLSA 11/25/20 Morgan Stanley OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley 10/26/20 JPMorgan TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday) TAL TAL Education $67.73 / -0.6 (-0.88%) 10/22/20 TAL Education sees Q3 revenue $1.06B-$1.09B, consensus $1.14B 10/22/20 TAL Education reports Q2 EPS 8c, consensus 12c 07/30/20 TAL Education sees Q2 revenue $1.08B-$1.11B, consensus $1.24B 07/30/20 TAL Education reports Q1 EPS 18c, consensus 1c TAL TAL Education $67.73 / -0.6 (-0.88%) 08/07/20 Citon says authorities given info to end GSX Techedu 'charade' 08:00 Today TAL Education - TAL TAL TAL Education $67.73 / -0.6 (-0.88%) 09/03/20 Tal Education Group put volume heavy and directionally bearish

Upgrade	Nordic Entertainment upgraded to Buy from Hold at Nordea » 05:19 01/21/21 01/21 05:19 01/21/21 05:19 NENTF Nordic Entertainment $0.00 / + (+0.00%) Nordea analyst Klas… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research NENTF Nordic Entertainment $0.00 / + (+0.00%) 12/04/20 Morgan Stanley Nordic Entertainment upgraded to Overweight from Equal Weight at Morgan Stanley 11/18/20 Berenberg Nordic Entertainment initiated with a Buy at Berenberg 05/18/20 Morgan Stanley Nordic Entertainment price target lowered to SEK 230 at Morgan Stanley
Downgrade	Fluidra downgraded to Hold from Buy at Santander » 05:18 01/21/21 01/21 05:18 01/21/21 05:18 FLUIF Fluidra $0.00 / + (+0.00%) Santander analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research FLUIF Fluidra $0.00 / + (+0.00%) 01/08/21 Berenberg Fluidra price target raised to EUR 22 from EUR 18 at Berenberg 12/03/20 HSBC Fluidra downgraded to Hold from Buy at HSBC 10/30/20 Berenberg Fluidra price target raised to EUR 18 from EUR 17.50 at Berenberg 10/29/20 JPMorgan Fluidra price target raised to EUR 17 from EUR 16 at JPMorgan
Upgrade	Ternium upgraded to Outperform from Neutral at Bradesco BBI » 05:17 01/21/21 01/21 05:17 01/21/21 05:17 TX Ternium $30.26 / -0.06 (-0.20%) Bradesco BBI analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TX Ternium $30.26 / -0.06 (-0.20%) 10/13/20 Ternium falls -11.5% TX Ternium $30.26 / -0.06 (-0.20%) 11/24/20 UBS Ternium upgraded to Neutral from Sell at UBS 11/06/20 Fly Intel: Top five analyst upgrades 11/06/20 JPMorgan Ternium upgraded to Overweight on steel recovery at JPMorgan 11/06/20 JPMorgan Ternium upgraded to Overweight from Neutral at JPMorgan TX Ternium $30.26 / -0.06 (-0.20%) 11/03/20 Ternium sees Q4 EBITDA up from Q3 11/03/20 Ternium reports Q3 EPS 74c, consensus 26c TX Ternium $30.26 / -0.06 (-0.20%) 11/03/20 Fly Intel: After-Hours Movers
Upgrade	Usiminas upgraded to Outperform from Neutral at Bradesco BBI » 05:17 01/21/21 01/21 05:17 01/21/21 05:17 USNZY Usiminas $0.00 / + (+0.00%) Bradesco BBI analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research USNZY Usiminas $0.00 / + (+0.00%) 09/17/20 Credit Suisse Usiminas upgraded to Neutral from Underperform at Credit Suisse 09/02/20 JPMorgan Usiminas upgraded to Overweight from Neutral at JPMorgan 07/24/20 Itau BBA Usiminas upgraded to Outperform from Market Perform at Itau BBA 06/19/20 Bradesco BBI Usiminas upgraded to Neutral from Underperform at Bradesco BBI
Upgrade	Skandinaviska Enskilda upgraded to Hold from Reduce at Kepler Cheuvreux » 05:16 01/21/21 01/21 05:16 01/21/21 05:16 SVKEF Skandinaviska Enskilda $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research SVKEF Skandinaviska Enskilda $0.00 / + (+0.00%) 01/11/21 UBS Skandinaviska Enskilda price target raised to SEK 91 from SEK 85 at UBS 01/07/21 Credit Suisse Skandinaviska Enskilda downgraded to Underperform from Neutral at Credit Suisse 01/07/21 Credit Suisse Skandinaviska Enskilda downgraded to Underperform from Neutral at Credit Suisse 11/19/20 AlphaValue Skandinaviska Enskilda upgraded to Reduce from Sell at AlphaValue

Downgrade	Pearson downgraded to Neutral from Outperform at Exane BNP Paribas » 05:14 01/21/21 01/21 05:14 01/21/21 05:14 PSO Pearson $10.04 / +0.79 (+8.54%) Exane BNP Paribas analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PSO Pearson $10.04 / +0.79 (+8.54%) 12/02/20 Pearson announces Mike Howells as new Chief Strategy Officer 10/14/20 Pearson 'on track' to deliver 2020 outturn in line with expectations 08/24/20 Pearson names Disney executive Andy Bird as new CEO, effective October 19 PSO Pearson $10.04 / +0.79 (+8.54%) 01/12/21 Berenberg Pearson price target raised to 475 GBp from 450 GBp at Berenberg 12/17/20 UBS Pearson price target raised to 750 GBp from 650 GBp at UBS 12/09/20 Fly Intel: Top five analyst downgrades 12/09/20 Kepler Cheuvreux Pearson cut to Reduce at Kepler Cheuvreux after recent share price rally PSO Pearson $10.04 / +0.79 (+8.54%) 10/14/20 Pearson reports Q3 revenue down 10% y/y vs. down 28% in Q2 07/24/20 Pearson reports 1H EPS 6.3p versus 6.1p in 1H19
Hot Stocks	Silvercorp Metals to acquire exploration rights to Zhonghe Project for $76M » 05:13 01/21/21 01/21 05:13 01/21/21 05:13 SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) Silvercorp Metals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Options SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 01/15/21 Silvercorp Metals reports production of ~900 ounces of gold in Q3 08/31/20 Silvercorp reports 18% increase in measured and indicated silver resources 07/28/20 Avalon Investment Holdings announce $4.5M investment of Silvercorp Metals SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 09/14/20 Canaccord Silvercorp Metals initiated with a Hold at Canaccord 09/01/20 BMO Capital Silvercorp Metals price target raised to C$10.50 from C$8.25 at BMO Capital 08/28/20 PI Financial Silvercorp Metals price target raised to C$10 from C$9 at PI Financial 08/10/20 BMO Capital Silvercorp Metals price target raised to C$8.25 from C$6.75 at BMO Capital SVM Silvercorp Metals $6.14 / +0.33 (+5.68%) 11/16/20 Sixteen new option listings and one option delisting on November 16th
Upgrade	ASML upgraded to Buy from Neutral at New Street » 05:13 01/21/21 01/21 05:13 01/21/21 05:13 ASML ASML $549.78 / +0.02 (+0.00%) New Street Research… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Periodicals Events ASML ASML $549.78 / +0.02 (+0.00%) 01/19/21 Barclays ASML price target raised to EUR 525 from EUR 475 at Barclays 01/15/21 JPMorgan ASML price target raised to EUR 437 from EUR 408 at JPMorgan 01/14/21 Barclays ASML price target raised to EUR 475 from EUR 425 at Barclays 01/13/21 UBS ASML price target raised to EUR 430 from EUR 395 at UBS ASML ASML $549.78 / +0.02 (+0.00%) 01/20/21 ASML sees Q1 net sales EUR 3.9B-EUR 4.1B, gross margin 50%-51% 01/20/21 ASML reports Q4 EPS EUR 3.23 vs. EUR 2.54 last quarter 10/14/20 ASML sees Q4 revenue EUR3.6B-EUR3.8B 10/14/20 ASML reports Q3 EPS EUR2.54 vs. EUR1.79 last quarter ASML ASML $549.78 / +0.02 (+0.00%) 11/13/20 TSMC places EUV equipment orders with ASML for 2021, DigiTimes reports 02/11/21 Technology & Internet Virtual Conference 01/26/21 ASML 01/27/21 ASML
Downgrade	Corteva downgraded to Neutral from Buy at Redburn » 05:12 01/21/21 01/21 05:12 01/21/21 05:12 CTVA Corteva $43.67 / +0.15 (+0.34%) Redburn analyst Tony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events CTVA Corteva $43.67 / +0.15 (+0.34%) 01/19/21 Matrix Service subsidiary awarded construction of water facility by Corteva 01/04/21 Corteva welcomes new Chief Technology Officer Sam Eathington 12/23/20 Tyson Foods appoints Megan Britt as VP, investor relations 11/13/20 Starboard Value takes Corteva stake, exits eBay CTVA Corteva $43.67 / +0.15 (+0.34%) 01/19/21 Deutsche Bank Corteva named 'Catalyst Call: Buy Idea' at Deutsche Bank 01/08/21 Deutsche Bank Corteva price target raised to $50 from $40 at Deutsche Bank 12/18/20 Susquehanna Corteva downgraded to Neutral from Positive at Susquehanna 12/14/20 Morgan Stanley Morgan Stanley upgrades Corteva, points to five reasons for above-consensus view CTVA Corteva $43.67 / +0.15 (+0.34%) 11/04/20 Corteva backs FY20 operating EPS view $1.25-$1.45, consensus $1.38 11/04/20 Corteva reports Q3 adjusted EPS (39c), consensus (42c) 11/04/20 Notable companies reporting after market close 08/05/20 Corteva sees FY20 operating EPS $1.25-$1.45, consensus $1.40 CTVA Corteva $43.67 / +0.15 (+0.34%) 11/19/20 Corteva board backs CEO amid pressure from Starboard, Reuters says 10/09/20 Starboard makes new bets on Corteva, ON Semiconductor, Reuters reports 02/04/21 Corteva - CTVA
Upgrade	BillerudKorsnas upgraded to Buy from Hold at Pareto » 05:12 01/21/21 01/21 05:12 01/21/21 05:12 BLRDF BillerudKorsnas $0.00 / + (+0.00%) Pareto analyst Axel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BLRDF BillerudKorsnas $0.00 / + (+0.00%) 06/23/20 Jefferies BillerudKorsnas downgraded to Underperform from Hold at Jefferies 05/28/20 Citi BillerudKorsnas downgraded to Neutral from Buy at Citi 04/27/20 Kepler Cheuvreux BillerudKorsnas upgraded to Buy from Hold at Kepler Cheuvreux

Events

Earnings calls, analyst events, roadshows and more

SI
Today at 08:00

Silvergate Capital - SI Conference Calls
BEDU
Today at 08:00

Bright Scholar - BEDU Conference Calls
DFS
Today at 08:00

Discover - DFS Conference Calls
WNS
Today at 08:00

WNS Holdings - WNS Conference Calls
TAL
Today at 08:00

TAL Education - TAL Conference Calls
STL
Today at 08:00

Sterling Bancorp - STL Conference Calls
TFC
Today at 08:00

Truist Financial - TFC Conference Calls
CTXS
Today at 08:15

Citrix - CTXS Conference Calls
PLXS
Today at 08:30

Plexus - PLXS Conference Calls
UNP
Today at 08:45

Union Pacific - UNP Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush Priced at: $13.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen Priced at: $26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities Priced at: $22.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading Priced at: $8.50 11.765M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel Priced at: $28.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.30 7.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright $93.33 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler $8.48 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $76.12 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse $72.11 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $ Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INO X INO Inovio Spot Secondary Managers: BofA, Jefferies & Cantor Fitzgerald, Oppenheimer $8.50-9.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONCS X ONCS OncoSec Spot Secondary Managers: BTIG $5.76 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares DCBO X DCBO Docebo Secondary Managers: Morgan Stanley, Goldman Sachs & Canaccord $70.51 3.65M Shares NVTA X NVTA Invitae Secondary Managers: JPMorgan, Morgan Stanley, Cowen & SVB Leerink $56.93 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SI X SI Silvergate Capital Secondary Managers: Goldman Sachs, Keefe Bruyette & Canaccord, Compass Point, Craig-Hallum $66.43 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Edesa Biotech completes enrollment of over 50% of patients for EB01 cream cohort

TODAY'S FREE FLY STORIES

Get Full Fly Access